Publications by authors named "T J Brennan"
Evidence That Regulatory And Market Forces Are Driving Adoption Of Biosimilars.
Health Aff (Millwood)
November 2024
Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However, the lackluster performance of the US biosimilar market in its first decade was met with disappointment and concern for its future viability. To evaluate the evolution of the biosimilar market, we reviewed key distinctions in medication classes and the financial stakeholders involved in each.
View Article and Find Full Text PDFArticle Synopsis
- - Bronchiolitis obliterans syndrome (BOS) is a serious lung condition that can develop after receiving a stem cell transplant, and this study tested the effectiveness of ruxolitinib in treating it.
- - The trial involved 49 adult participants divided into two groups based on how recently they were diagnosed with BOS; results showed that 27.8% of newly diagnosed patients improved, while 92.3% of those with established BOS maintained stable lung function after treatment.
- - Overall, ruxolitinib had a lung-specific response rate of 34.7% among all participants with most positive outcomes seen in patients with mild to moderate disease, indicating it could be a beneficial treatment option for BOS
Background: Serum AFP-L3%, AFP, and DCP are useful biomarkers for HCC detection, but their utility in assessing treatment response remains unknown. We aim to evaluate the accuracy of a biomarker model in the detection of posttreatment viable tumors.
Methods: For model derivation, recipients with HCC undergoing liver transplant from 2018 to 2022 who had biomarkers collected within 3 months before transplant were included.